Company Overview and News

NCNA / NuCana plc 6-K (Current Report of Foreign Issuer)


NuCana CEO Hugh Griffith Honored with the Outstanding Achievement Award from Life Sciences Scotland

2018-05-17 globenewswire
EDINBURGH, United Kingdom, May 17, 2018 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced today it has been honored with two prestigious awards from Life Sciences Scotland during its annual Life Sciences Awards gala event held in Glasgow on May 16, 2018. Hugh S. Griffith, Chief Executive Officer and Founder, was presented with the Outstanding Contribution award. Additionally, NuCana was awarded Investment of the Year.

NCNA / NuCana plc null

begin 644 filename1.pdf M)5!$1BTQ+C4-)>+CS],-"C$P(# @;V)J#3P\+TQI;F5A#0IE;F1S M=')E86T-96YD;V)J#7-T87)T>')[email protected]*, T*)25%3T8-"B @(" @(" @#0HR M,B P(&]B:@T\/"]&:6QT97(O1FQA=&5$96-O9&4O22 X-"],(#8X+TQE;F=T M:" V,"]3(#,X/CYS=')E86T-"FC>[email protected][email protected]

NCNA / NuCana plc 6-K (Current Report of Foreign Issuer)


Stocks To Watch: Back To School For Apple

2018-03-24 seekingalpha
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.

NCNA / NuCana plc 20-F

ncna-20f_20171231.htm As filed with the Securities and Exchange Commission on March 22, 2018 UNITED STATES

NCNA / NuCana plc 6-K (Current Report of Foreign Issuer)


NCNA / NuCana plc FORM S-8

Form S-8 As filed with the Securities and Exchange Commission on March 6, 2018 Registration No. 333-

ROTY Volume 1 Edition 83: Thank You For Your Patience - Launch Day Has Arrived!

2018-03-01 seekingalpha
We start this final public edition by answering a few questions regarding the service, such as why I decided to start it.

ROTY Edition 1 Volume 82: Launch Preview And Adding To A Position

2018-02-23 seekingalpha
I remind readers of my recent blog post which gives a preview of the ROTY MarketPlace launch to help them decide if the service is appropriate for their needs.

ROTY Edition 1 Volume 81: We Have A Launch Date!

2018-02-21 seekingalpha
February continues to be our worst month yet, but I focus on positioning the model account for success based on our current plan.

ROTY Edition 1 Volume 80: Adding To Select Positions And Continuing To Manage Risk

2018-02-16 seekingalpha
I remind readers of our biggest loser to date and why risk management has been key to ROTY`s success.

ROTY Edition 1 Volume 79: Limited Downside Catalysts Vs. Binary Risk

2018-02-14 seekingalpha
We discuss the difference between binary catalysts and those with limited downside, utilizing two recent examples.

ROTY Edition 1 Volume 78: Simplify Your Decision-Making And Stick To Guidelines

2018-02-13 seekingalpha
As always, readers are encouraged to do their own due diligence, manage risk appropriately, and avoid blindly following.

ROTY Edition 1 Volume 77: Market Turmoil Continues - How To React

2018-02-09 seekingalpha
Recent market volatility is addressed and we discuss in depth how to react while sticking to one´s plan.

Related Articles

ANTH: Anthera Pharmaceuticals Analysis and Research Report

2018-05-21 - Asif

Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...

AGEN: Agenus Inc Analysis and Research Report

2018-05-21 - Asif

Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...

SQ: Square Analysis and Research Report

2018-05-21 - Asif

Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...

CUSIP: 67022C106